Abstract:Background: Risk stratification in Brugada syndrome (BrS) is based on the occurrence of dynamic factors, such as unexplained syncope and documentation of spontaneous type 1 pattern. At odds with other channelopathies, the role of nonmodifiable risk factors such as sex or genetics remains uncertain. Objectives: This study aims to identify nonmodifiable risk factors for the occurrence of life-threatening arrhythmic events (LAEs) and define their clinical utility. Methods: Clinical and genetic data from consecutive, unrelated Italian patients with Brugada syndrome screened on the sodium voltage-gated channel alpha subunit 5 (SCN5A) gene and 3 pivotal single-nucleotide variations (formerly single-nucleotide polymorphisms) associated with BrS (rs11708996, rs10428132, and rs9388451) were analyzed using multivariable Cox proportional hazards model. Results: In 2,182 unrelated patients with BrS (81% males; median age at diagnosis: 41.6 years [Q1-Q3: 33.4-50.3 years]), male sex (HR: 3.6; 95% CI: 1.9-6.9; P = 0.0001), missense SCN5A mutations in BrS-enriched domains (HR: 2.3; 95% CI: 1.2-4.3; P = 0.008), nonmissense SCN5A mutations (HR: 3.2; 95% CI: 1.8-5.7; P < 0.001), and polygenic risk score for BrS (HR: 1.3; 95% CI: 1.0-1.6; P = 0.041) were all independently associated with a significantly higher risk of a first LAE since birth. Based on these results, we derived the nonmodifiable risk of each patient with BrS, and the division of nonmodifiable risk into tertiles identified 3 distinct risk profiles. In an analysis at follow-up, nonmodifiable risk was independently associated with LAE at follow-up (HR: 1.8; 95% CI: 1.1-2.7; P = 0.014), alongside classical predictors including: history of LAE before diagnosis (HR: 13.8; 95% CI: 8.1-23.7; P < 0.0001), history of unexplained syncope before diagnosis (HR: 4.1; 95% CI: 2.4-6.8; P < 0.0001), and spontaneous type 1 pattern at diagnosis (HR: 2.1; 95% CI: 1.2-3.8; P = 0.010). The model was internally validated, and we derived the equation permitting to calculate the granular 5-year risk of experiencing an LAE at follow-up for each patient with BrS, which may be used to facilitate clinical decision-making. Conclusions: Our data show that male sex, type of SCN5A mutation, and polygenic risk score for BrS define the nonmodifiable risk of each patient with BrS. Nonmodifiable risk is independently associated with LAE, regardless of symptoms or pattern type.

Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Profile of Patients with Brugada Syndrome Presenting with Their First Documented Arrhythmic Event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS).

Ventricular conduction delay as marker of risk in Brugada Syndrome. Results from the analysis of clinical and electrocardiographic features of a large cohort of patients

Prediction and Prevention of Sudden Death in the Brugada Syndrome

Programmed Ventricular Stimulation: Risk Stratification and Guiding Antiarrhythmic Therapies

Pathogenesis and Management of Brugada Syndrome: Recent Advances and Protocol for Umbrella Reviews of Meta-Analyses in Major Arrhythmic Events Risk Stratification

Implantable loop recorders in patients with Brugada syndrome: the BruLoop study

Catheter ablation as an adjunctive therapy to ICD implantation in Brugada Syndrome

Time-to-first Appropriate Shock in Patients Implanted Prophylactically with an Implantable Cardioverter-Defibrillator: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS)

Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: A nationwide cohort registry study

Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome

Age of First Arrhythmic Event in Brugada Syndrome

Electrophysiological patterns and structural substrates of Brugada syndrome: Critical appraisal and computational analyses

Characterization and Management of Arrhythmic Events in Young Patients with Brugada Syndrome.

Brugada syndrome: identification of subjects at risk and therapy

High‐risk atrioventricular block in Brugada syndrome patients with a history of syncope

Genotype-Phenotype Correlation of SCN5A Genotype in Patients with Brugada Syndrome and Arrhythmic Events Insights from the SABRUS in 392 Probands

Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study

Non-invasive cardiac activation mapping and identification of severity of epicardial substrate in Brugada Syndrome: a case report